GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » Cyclically Adjusted Price-to-FCF

NeuroMetrix (NeuroMetrix) Cyclically Adjusted Price-to-FCF : (As of Apr. 28, 2024)


View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeuroMetrix Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for NeuroMetrix's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix Cyclically Adjusted Price-to-FCF Chart

NeuroMetrix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeuroMetrix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeuroMetrix's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, NeuroMetrix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroMetrix's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroMetrix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NeuroMetrix's Cyclically Adjusted Price-to-FCF falls into.



NeuroMetrix Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

NeuroMetrix's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, NeuroMetrix's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.256/129.4194*129.4194
=-1.256

Current CPI (Dec. 2023) = 129.4194.

NeuroMetrix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -806.000 99.695 -1,046.317
201406 -925.000 100.560 -1,190.469
201409 -655.000 100.428 -844.086
201412 -826.333 99.070 -1,079.478
201503 -939.667 99.621 -1,220.737
201506 -968.500 100.684 -1,244.913
201509 -704.600 100.392 -908.333
201512 -695.800 99.792 -902.374
201603 -607.833 100.470 -782.971
201606 -600.714 101.688 -764.534
201609 -461.750 101.861 -586.676
201612 -454.500 101.863 -577.455
201703 -258.000 102.862 -324.611
201706 -203.625 103.349 -254.990
201709 -114.720 104.136 -142.574
201712 -102.355 104.011 -127.359
201803 11.942 105.290 14.679
201806 5.810 106.317 7.073
201809 2.374 106.507 2.885
201812 -4.368 105.998 -5.333
201903 2.400 107.251 2.896
201906 -19.850 108.070 -23.772
201909 -14.246 108.329 -17.019
201912 -0.401 108.420 -0.479
202003 -4.192 108.902 -4.982
202006 -2.836 108.767 -3.374
202009 -1.091 109.815 -1.286
202012 0.593 109.897 0.698
202103 -0.116 111.754 -0.134
202106 -1.146 114.631 -1.294
202109 -1.424 115.734 -1.592
202112 -0.625 117.630 -0.688
202203 -0.866 121.301 -0.924
202206 -0.968 125.017 -1.002
202209 -2.555 125.227 -2.641
202212 -1.566 125.222 -1.618
202303 -1.166 127.348 -1.185
202306 -1.472 128.729 -1.480
202309 -1.936 129.860 -1.929
202312 -1.256 129.419 -1.256

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeuroMetrix  (NAS:NURO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


NeuroMetrix Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroMetrix (NeuroMetrix) Business Description

Traded in Other Exchanges
N/A
Address
4B Gill Street, Woburn, MA, USA, 01801
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Executives
Bradley M Fluegel director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins officer: Chief Financial Officer
Topline Capital Management, Llc other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp 10 percent owner 544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani director, officer: Chairman, President and CEO C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin officer: Senior VP, Consumer C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van director C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran officer: S. VP and GM, International C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz director CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc officer: Senior Vice President & GM
Walter Christensen officer: Sr. VP, Global Sales C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor director 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C) 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017